Siemens Introduces a New Generation in Preclinical Imaging -- MEDICA - World Forum for Medicine


Siemens AG Medical Solutions

Siemens Introduces a New Generation in Preclinical Imaging

Siemens Medical Solutions introduced Inveon, a new preclinical, multimodality im-aging solution, which enhances research and drug discovery. Inveon can help facili-tate basic research as well as the drug development process, empowering re-searchers to identify specific biological processes. Four installations of this new solution are already installed in university research facilities in Europe.

Inveon can help facilitate basic research as well as the drug development process, em-powering researchers to identify specific biological processes, monitor the efficacy of com-pounds, and measure the effects of disease progression over time. Molecular medicine combines advanced imaging with molecular biomarkers to enable the identification of dis-ease pathways and evaluate the actions of novel therapies. As more disease-specific bio-markers are developed, researchers may be able to increase the speed at which drugs come to market in the future.

Available as a modular or integrated system Inveon enables researchers to leverage any combination of Siemens’ preclinical hybrid imaging systems and leading edge applications for improved research opportunities. It offers a versatile and upgradeable platform as well as a comprehensive suite of preclinical analysis applications. The system enables unified control of Positron Emission Tomography (PET), Single-Photon Emission Computed To-mography (SPECT), and CT data acquisition, and offers the industry’s highest PET resolu-tion and sensitivity. Inveon features advanced multi-pinhole SPECT collimators for im-proved sensitivity and spatial resolution; groundbreaking new PET and SPECT acquisition and processing technology; and a unique PET transmission method for fast and accurate attenuation correction.

In addition to enhanced imaging capabilities, Siemens has expanded its preclinical applications, which includes the most comprehensive suite of reconstruction algorithms offered in the industry. Inveon offers optimized data acquisition and state of the art image fusion technology, high end integrated visualization and analysis capabilities and comprehensive preclinical data analysis and post process applications.

Inveon offers researchers the convenience of a multimodality platform with the potential throughput of two independent scanners. A dedicated PET module can be used as a standalone, high-performance small animal imaging system, or docked onto the Inveon gantry, housing CT and/or SPECT modules. When in the docked configuration, the system can operate independently or as a single unit under the control of one workstation. In-veon’s integrated and modular configurations are customizable to specific needs, optimiz-ing throughput and making PET/CT, CT/SPECT, or PET/CT/SPECT configurations possi-ble.

“Siemens preclinical solutions are driving medical research from the laboratory to the clinic,” said Michael Reitermann, president, Molecular Imaging Division, Siemens Medical Solutions. “Inveon offers limitless solutions and the highest performance and versatility available to address research needs from academic and translational research, to drug discovery and development.”

Siemens Medical Solutions of Siemens AG (NYSE: SI) is one of the world’s largest suppliers to the health-care industry. The company is known for bringing together innovative medical technologies, healthcare in-formation systems, management consulting, and support services, to help customers achieve tangible, sus-tainable, clinical and financial outcomes. Recent acquisitions in the area of in-vitro diagnostics – such as Diagnostic Products Corporation and Bayer Diagnostics – mark a significant milestone for Siemens as it becomes the first full service diagnostics company. Employing more than 41,000 people worldwide and op-erating in over 130 countries, Siemens Medical Solutions reported sales of 8.23 billion EUR, orders of 9.33 billion EUR and group profit of 1.06 billion EUR for fiscal 2006 (Sept. 30). Further information can be found by visiting